MICHAEL MATHISEN: Open Payments
NPI 1114487881 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,490 in 77 payments from 13 companies in 2025. Trend: 2023 $2,432 · 2024 $1,996 · 2025 $2,490
Food & beverage: $2,490
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $647 |
| E.R. Squibb & Sons, L.L.C. | 12 | $363 |
| Otsuka America Pharmaceutical, Inc. | 11 | $344 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $257 |
| ABBVIE INC. | 8 | $236 |
| Janssen Pharmaceuticals, Inc | 5 | $194 |
| Alkermes, Inc. | 6 | $175 |
| Teva Pharmaceuticals USA, Inc. | 4 | $102 |
| Almatica Pharma LLC | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
Products named: INGREZZA, COBENFY, CAPLYTA, VRAYLAR, REXULTI, ARISTADA, SPRAVATO, ABILIFY MAINTENA.
Industry payments across NV — which companies pay providers there.
